Navigation Links
NeoPharm Provides Update on LE-SN38 Program

WAUKEGAN, Ill.--(BUSINESS WIRE)--Mar 30, 2007 - NEOPHARM, Inc. (Nasdaq: NEOL) today reported findings from a Phase 2 clinical trial in second-line metastatic colorectal cancer patients with its drug product candidate LE-SN38, the active metabolite of irinotecan (Camptosar(R)). While the interim analysis of data following the completion of treatment of the first 21 patients demonstrated disease stabilization, the study did not achieve the primary tumor response endpoint. No new patient accrual will be made into this study conducted by the Cancer and Leukemia Group B (CALGB), a national clinical research group sponsored by the National Cancer Institute (NCI). Patients currently receiving therapy will continue treatment per protocol until a study endpoint is reached. NeoPharm will be reassessing project next steps including additional data analyses and the possibility of other studies.

About NEOPHARM, Inc.

NEOPHARM, Inc., based in Waukegan, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. Additional information, including ongoing clinical trials, can be obtained by visiting NEOPHARM's Web site at www.neopharm.com.

Forward Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's drug development program, the initiation, progress and outcomes of clin
'"/>




Page: 1 2

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. XTL Provides Update on Phase I Clinical Trial of XTL-2125
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
5. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
6. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
7. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
8. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
9. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
10. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
11. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NeoPharm Provides Update Program
(Date:5/22/2013)... 22, 2013 Z-Medica, a leading developer and ... the first-ever line of products designed to meet the ... QuikClot ® EMS 4x4 Dressing, QuikClot ® ... Rolled Gauze™, all custom-designed to help responders stop bleeding ... transported to a hospital or trauma center. The line ...
(Date:5/22/2013)... -- MGT Capital Investments, Inc. (NYSE MKT: MGT) announced today ... Marcum LLP MicroCap Conference on Thursday, May 30, 2013 ... the Grand Hyatt Hotel.  Robert Ladd ... and answer questions. (Logo: http://photos.prnewswire.com/prnh/20130409/NY91046LOGO ... begin at 9:30 a.m. EDT.  MGT,s latest presentation materials ...
(Date:5/22/2013)... NEW ORLEANS , May 22, 2013 /PRNewswire/ ... period for commercially-insured patients with Type 2 diabetes, ... shown to improve health outcomes and can lead ... studies presented at the International Society for Pharmacoeconomics ... The two studies, sponsored by Valeritas, ...
Breaking Medicine Technology:Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6
... AUSTIN, Texas, Aug. 17 Luminex Corporation (Nasdaq: ... today announced it has donated the first commercial unit ... Siba and his scientific team at the Papua New ... used onsite in Papua New Guinea to progress malaria ...
... RENO, Nev., Aug. 17 Equinox Surgical Solutions ... product, SutureAssist® , designed and developed by a ... Volker M.D., Ph.D. and his team to improve ... surgeons and scrub techs acquire, hand-off, dispose of and ...
Cached Medicine Technology:Luminex Donates Company's First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research 2Luminex Donates Company's First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research 3Equinox Surgical Solutions Launches Flagship Product, SutureAssist® 2
(Date:5/22/2013)... May 22, 2013 TheBeautyPlace.com features Toppik and ... cover up any remnants of thinning or balding hair. Hair ... conceal the appearance of hair loss during this waiting period, ... be used as an alternative to hair transplant surgery in ... a safe and an extremely effective way to eliminate the ...
(Date:5/22/2013)... 2013 NBA Draft tickets go on sale ... 2013. , The 2013 NBA Draft will be held at the ... the Brooklyn Nets. The Barclays Center has already become a ... such as Paul McCartney and Beyonce have already booked sold out ... will also perform at this state-of-the-art venue. Disney on Ice ...
(Date:5/22/2013)... Today, at the World Health Assembly, top health officials ... met to discuss the vital need for countries to ... prevention and control into national action plans. , "RHD ... years ago but today it remains as a disease ... in their most productive years, said Dr K. Srinath ...
(Date:5/22/2013)... (HealthDay News) -- Use of the antidepressant Lexapro ... heart condition, a new study finds. ... stress-induced myocardial ischemia." Although people with this condition ... is not receiving adequate blood supply, according to ... Durham, N.C. However, the researchers found that ...
(Date:5/22/2013)... Teams who focus on productivity, process, quality, 5S ... StepTracker whiteboard as a rallying point for project management ... the current status of our company-wide lean initiatives and ... listed down the side and the milestones are along ... are filled with yellow circles. Turning the magnets over ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Divulges Two Innovative Hair Loss Concealers on the Market Today: Bosley Hair Thickening Fibers and Toppik Hair Building Fibers 2Health News:2013 NBA Draft Tickets: Cheap Concert Tickets Announces that Official Onsales for the 2013 NBA Draft Begin at 10:00 am Local Time on Wednesday, May 22, 2013 2Health News:Governments hold long-overdue meeting on reducing early death from rheumatic heart disease 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 3Health News:Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards 2
... by Ohio State University that chose to study the mind-set of ... no compunctions opening up to others about their HIV status. ... study Julianne Serovich says, “I was very surprised at how little ... who deliberate very carefully on whether or not to tell people. ...
... was found that via online auction home-made ecstasy kit ... that// eBay sold various chemicals. The purchase was done ... done varying from laboratory and security equipment to precursor ... from July 2005 to April 2006. Local Investigators were ...
... results about a three-stage brain surgery, performed on 25 ... intractable seizures. ,Sadly, none of the treatments ... a special diet —could quell the electrical storms in ... disease called tuberous sclerosis, the seizures began when he ...
... Health conscious people here lawyers in California have sued PepsiCo ... benzene//., ,The drink in question is Pepsi Twist drink, ... three' soft drinks firms has been drawn into a legal ... the lawsuit, "Pepsi Twist has been falsely promoted as a ...
... research from Kansas State University have revealed that males tend ... whereas women on average often// use more protective strategies such ... spent on drinking, counting the number of drinks, and eating ... from the point of view of a whole class of ...
... which is believed to play a key role in the ... added that the revelation could be of immensely helpful for ... of an enzyme called telomerase is believed to contribute to ... human tumors. A lack of detailed information regarding its structure ...
Cached Medicine News:Health News:Intractable Seizures Can Be Handled By A Three-Stage Brain Operation, Neurosurgeon 2Health News:Intractable Seizures Can Be Handled By A Three-Stage Brain Operation, Neurosurgeon 3
... The Vision5L Digital ... 5- or 7-lead, ... a signal preview,screen. ... using a compact,flash ...
... The Burdick EK-10 ... one-button,soft touch membrane keypad. ... to make a quick ... is ergonomically,designed with a ...
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... CSV-1000LanC 10% test face is ... uses the Landolt C in ... targets. The targets are presented ... is very useful for evaluating ...
Medicine Products: